Tuesday, October 11, 2022

PFIZER'S PRESIDENT OF INT'L DEVELOPED MARKETS SAYS, "We had to really move at the speed of science to really understand what [was] taking place in the market."

Her name is Janine Small, and she is the President of International Developed Markets at Pfizer.

Her audience is the EU Parliament, so this is like singing to the choir.  Her interrogator is Rob Roos, an MEP.

Roos:  Was the Pfizer COVID vaccine tested on stopping the transmission of the virus before it entered the market?  If not, please say it clearly.  If yes, are you willing to share the data with this committee?  And I really want straight answer, yes or no, and I am looking forward to it.  Thank you very much. 

Small, 0:35:  Um, regarding the question around, um, "Did we know about stopping immunization before it entered the market?"  No [she laughs].  We had to really move at the speed of science to really understand what [was] taking place in the market.  

And from that point of view, we had to do everything at risk.  I think it was Dr. [Albert] Bourla, even though he's not here, would turn around and say to you himself that "If not us, then who?"  Dr. Bourla actually felt the importance of what was going on in the world.  ["felt"?]  And therefore, as a result of that, we actually spent $2 billion dollars at risk of self-funded money from Pfizer [I believe countries around the world indemnified the vaccine manufacturers, meaning no risk to them] to be able to manufacture . . . first of all, research, develop, and manufacture at risk to be able to make sure that we were in a position to be able to help with the pandemic.  And I think that's why I feel very good when a recent paper from the Imperial College [and here, and owned and operated by Bill Gates' money] stated that in the first year of the rollout of vaccines we saved 4 million people.  So from that point of view, I feel, actually that we were there.  (Could she be more vague; could she say less than nothing by saying more than wanted?) when the world needed us.  (Wow, I don't remember thinking that I needed her or Pfizer or the Imperial College, do you?) to be able to make sure that we were able to help people around the world with vaccination as well as oral treatment.  I would hate to imagine what situation we would be in the world right now if companies like ours did not take those risks, did not do clinical research [you didn't do clinical research] and development at scale in order to have a vaccine that we could rollout to the world.  I understand your frustrations, I really do, but I also hope that at some point, somewhere you also do appreciate what pharmaceutical companies have done to rollout and deliver vaccines at such speed and scale. 

Since we're talking about scale, Ms. Small, did Imperial College or Dr. Bourla inform you these numbers, these global numbers?

No comments:

Post a Comment